Has Richard Stern received payments from drug or device companies?

Yes. Drug and device makers reported $580,813 in general payments to Richard Stern across 196 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Richard Stern did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Richard Stern come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Richard Stern

Cardiovascular Disease · San Pablo, CANPI 1760495337

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $576,032 of the $580,813 with a category attached, or 99.2%. Boston Scientific accounts for 99.2% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $188,355 and has fallen 65.6% since, to $64,796 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$580,813in general payments, 2019–2025

Across 196 payments — averaging $2963.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$576K
Medtronic$2K
Pfizer$442
Amgen$329
Novartis$315
Philips North America LLC$268
plus $1K from 15 others

What the payments were for

Consulting fees$576,03299%
Travel & lodging$1,5850%
Food & beverage$3,1301%
Education$670%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	80	$576,078
Medtronic	10	$2,090
Pfizer	18	$442
Amgen	8	$329
Novartis	17	$315
Philips North America LLC	10	$268
Sanofi-aventis U.S. LLC	9	$149
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	4	$139
Amarin Pharma, Inc.	10	$139
Johnson & Johnson	7	$139
Boehringer Ingelheim	7	$135
Radius Health, Inc.	1	$125
Actelion Pharmaceuticals US, Inc.	1	$122
Therapeuticsmd, Inc.	1	$77
Bayer	1	$66
E.r. Squibb & Sons, L.L.C.	4	$60
AstraZeneca	3	$52
Novo Nordisk	1	$24
Vanda Pharmaceuticals Inc.	2	$23
Irhythm Technologies, Inc.	1	$21
Regeneron Healthcare Solutions, Inc.	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$580,813 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Other cardiovascular disease in San Pablo

Ted LoveHillsborough$102.8M
Paul KurthSanta Barbara$6.1M
Jason RogersSacramento$4.4M
Matthew BudoffTorrance$3.6M
Eric Topolla Jolla$2.2M
Cathleen Bairey-MerzLos Angeles$1.2M
Gagan SinghSacramento$1.2M
Pam Taubla Jolla$1.2M
Wilber SuStanford$1.1M
Thomas SmithSacramento$942K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →